Bioalliance Pharma SA, of Paris, said it executed a license agreement with Innocutis Holding LLC, of Charleston, S.C., to commercialize Sitavig (acyclovir Lauriad) for the treatment of recurrent labial herpes in North America. Under the terms, Bioalliance is eligible to receive a total of $5 million up front and milestone payments.